J. Liang

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Lujun Zhao, Junling Li, Wei Jiang, 2019, BMC Cancer.

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

Wenjing Zhang, Yali Li, H. Tian, 2022, Frontiers in Pharmacology.

Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements

L. Yang, Huadan Xue, Zhengyu Jin, 2022, Liver Cancer.

The E cacy and Safety of Fruquintinib Plus PD-1 Inhibitor in ≥3 line MSS Metastatic Colorectal Cancer Patients

Xiang Wang, Xian-Bao Wang, Li Lin, 2021 .

Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review

Xiaotong Lu, J. Liang, Yunsong Liu, 2022, Frontiers in Immunology.

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature

Jianyang Wang, Zongmei Zhou, Q. Feng, 2022, Medicine.

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

W. Feng, H. Hong, Xiaotao Huang, 2022, Journal of Experimental & Clinical Cancer Research.

Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis

Peng Wang, J. Liang, Yu Zhang, 2022, BMC gastroenterology.